AltaThera Pharmaceuticals
Chicago, US · Delaware LLC
AltaThera develops intravenous antiarrhythmic therapies for treating cardiac conditions including atrial fibrillation and ventricular tachycardia. The company's lead product, Sotalol IV, enables faster patient assessment and potential outpatient discharge compared to oral alternatives.
Founders & leadership
MB
Merrill BardenExecutive
SO
Stephen O'SullivaninGeneral Counsel, Chief Compliance Officer, Director
JW
James WittenberginVice Presidentformer
BK
Brandon KashfianinFounder & Chief Business Officer
JE
John Ellis IIinFounder
MG
Maria GrayMA, RN, EdD
JP
Jim PerryMD
Board
JF
John FlavinBoard director
AS
Adam StrickbergerMD, FACC
Reported raises · per SEC filings
Form D private placements$7.6M disclosed across 6 rounds · 2014–2019
▶$1.5MraisedAug 2019 · 2 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedAug 2019 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Brandon KashfianExecutive Officer
- Jodi DevlinExecutive Officer
- Stephen OsullivanExecutive Officer
- Offering amount
- $4M
- Amount sold
- $1.5M
- Sales commissions
- $29.6K
- Placement agents
- Silverwood Partners
- First sale
- Apr 2019
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$3.4MraisedDec 2016 · 12 investors · PharmaceuticalsRule 506(b)
▶$3.4MraisedDec 2016 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stephen O?SullivanExecutive Officer, Director
- James WittenbergExecutive Officer
- Merrill BardenExecutive Officer
- Offering amount
- $3.5M
- Amount sold
- $3.4M
- Minimum investment
- $25K
- First sale
- Dec 2016
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$225KraisedNov 2016 · 4 investors · PharmaceuticalsRule 506(c)
▶$225KraisedNov 2016 · 4 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Brandon KashfianExecutive Officer, Director
- Merrill BardenExecutive Officer
- John SombergExecutive Officer
- James WittenbergExecutive Officer
- Rick WhiteExecutive Officer
- Jay WelshExecutive Officer
- Stephen O'SullivanExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $225K
- Sales commissions
- $80K
- Placement agents
- M Barc Investment Group, Inc.
- First sale
- Oct 2016
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06c
▶$1MraisedJul 2015 · 1 investors · PharmaceuticalsRule 506(c)
▶$1MraisedJul 2015 · 1 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Stephen O'SullivanExecutive Officer, Director
- Mahlaqa PatelExecutive Officer
- James WittenbergExecutive Officer
- John FlavinDirector
- Brandon KashfianExecutive Officer, Director
- Merrill BardinExecutive Officer
- Jay WelshExecutive Officer
- Offering amount
- $1M
- Amount sold
- $1M
- Minimum investment
- $1M
- Sales commissions
- $80K
- Placement agents
- M Barc Investment Group, Inc.
- First sale
- Jul 2015
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06c
▶$1MraisedFeb 2015 · 1 investors · PharmaceuticalsRule 506(b)
▶$1MraisedFeb 2015 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stephen O'SullivanExecutive Officer
- Brandon KashfianExecutive Officer
- John FlavinDirector
- Merrill BardenExecutive Officer
- James WittenbergExecutive Officer
- Offering amount
- $1M
- Amount sold
- $1M
- Minimum investment
- $1M
- Sales commissions
- $80K
- Placement agents
- M Barc Investment Group, Inc.
- First sale
- Oct 2014
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$500KraisedJan 2015 · 1 investors · PharmaceuticalsRule 506(b)
▶$500KraisedJan 2015 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Merrill BardenExecutive Officer
- Stephen O'SullivanExecutive Officer
- James WittenbergExecutive Officer
- John FlavinDirector
- Brandon KashfianExecutive Officer
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $500K
- Sales commissions
- $40K
- Placement agents
- M Barc Investment Group, Inc.
- First sale
- Mar 2014
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does AltaThera Pharmaceuticals do?
- AltaThera develops intravenous antiarrhythmic therapies for treating cardiac conditions including atrial fibrillation and ventricular tachycardia. The company's lead product, Sotalol IV, enables faster patient assessment and potential outpatient discharge compared to oral alternatives.
- How much funding has AltaThera Pharmaceuticals raised?
- AltaThera Pharmaceuticals has disclosed $7.6M raised across 6 rounds.
- Where is AltaThera Pharmaceuticals headquartered?
- AltaThera Pharmaceuticals is headquartered in Chicago, US.